Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 13 | 2024 | 317 | 3.520 |
Why?
|
| Lung Neoplasms | 13 | 2025 | 2365 | 1.650 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2025 | 1133 | 1.610 |
Why?
|
| Oropharyngeal Neoplasms | 7 | 2025 | 149 | 1.090 |
Why?
|
| Head and Neck Neoplasms | 6 | 2025 | 1073 | 1.070 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2024 | 129 | 1.010 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 776 | 1.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2025 | 2544 | 0.930 |
Why?
|
| Papillomavirus Infections | 6 | 2025 | 300 | 0.810 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 66 | 0.790 |
Why?
|
| Trachea | 1 | 2024 | 245 | 0.790 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 1077 | 0.770 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.740 |
Why?
|
| Tongue Neoplasms | 1 | 2022 | 51 | 0.710 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 17 | 0.670 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1395 | 0.660 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 63 | 0.660 |
Why?
|
| Pneumonia | 1 | 2022 | 193 | 0.650 |
Why?
|
| Mouth Neoplasms | 1 | 2022 | 202 | 0.620 |
Why?
|
| Chemoradiotherapy | 6 | 2025 | 326 | 0.610 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1723 | 0.580 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 418 | 0.560 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2018 | 15 | 0.560 |
Why?
|
| Immunotherapy | 5 | 2024 | 761 | 0.530 |
Why?
|
| Radiotherapy | 3 | 2024 | 320 | 0.530 |
Why?
|
| Humans | 46 | 2025 | 93515 | 0.460 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 620 | 0.460 |
Why?
|
| Carcinoma | 3 | 2024 | 439 | 0.450 |
Why?
|
| Prospective Studies | 6 | 2025 | 4560 | 0.390 |
Why?
|
| Esophagectomy | 1 | 2014 | 92 | 0.390 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 2017 | 0.390 |
Why?
|
| Postoperative Complications | 4 | 2019 | 2562 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 446 | 0.380 |
Why?
|
| DNA, Viral | 2 | 2025 | 234 | 0.380 |
Why?
|
| Carboplatin | 5 | 2025 | 322 | 0.380 |
Why?
|
| Anastomosis, Surgical | 1 | 2014 | 280 | 0.380 |
Why?
|
| Brain Neoplasms | 4 | 2019 | 813 | 0.370 |
Why?
|
| Aged | 21 | 2025 | 20434 | 0.350 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 344 | 0.340 |
Why?
|
| Radiation Injuries | 4 | 2024 | 158 | 0.330 |
Why?
|
| Middle Aged | 23 | 2025 | 27573 | 0.330 |
Why?
|
| Papillomaviridae | 4 | 2025 | 179 | 0.310 |
Why?
|
| Retrospective Studies | 14 | 2024 | 10164 | 0.310 |
Why?
|
| Male | 23 | 2025 | 44557 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1448 | 0.300 |
Why?
|
| Female | 25 | 2025 | 48702 | 0.300 |
Why?
|
| Survival Rate | 5 | 2024 | 1948 | 0.270 |
Why?
|
| Biomarkers, Tumor | 4 | 2025 | 1660 | 0.270 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 7061 | 0.270 |
Why?
|
| Adult | 17 | 2025 | 27918 | 0.260 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3830 | 0.240 |
Why?
|
| Sarcoma | 2 | 2018 | 222 | 0.240 |
Why?
|
| Ipilimumab | 2 | 2022 | 63 | 0.230 |
Why?
|
| Lymphopenia | 1 | 2025 | 31 | 0.220 |
Why?
|
| Patient-Specific Modeling | 1 | 2025 | 24 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2018 | 188 | 0.220 |
Why?
|
| Organ Sparing Treatments | 1 | 2024 | 47 | 0.210 |
Why?
|
| Thoracic Neoplasms | 1 | 2024 | 65 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 76 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 181 | 0.210 |
Why?
|
| Etoposide | 1 | 2024 | 204 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 161 | 0.200 |
Why?
|
| Neoplasms | 3 | 2024 | 3169 | 0.200 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2024 | 81 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 148 | 0.190 |
Why?
|
| Re-Irradiation | 1 | 2022 | 17 | 0.180 |
Why?
|
| Tongue | 1 | 2022 | 58 | 0.180 |
Why?
|
| Paclitaxel | 4 | 2025 | 479 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 49 | 0.170 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 3110 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2022 | 119 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 106 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2022 | 548 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 391 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 95 | 0.160 |
Why?
|
| Prognosis | 5 | 2022 | 3911 | 0.160 |
Why?
|
| Tissue Expansion | 1 | 2019 | 18 | 0.150 |
Why?
|
| Breast Implantation | 1 | 2019 | 14 | 0.150 |
Why?
|
| Breast Implants | 1 | 2019 | 27 | 0.150 |
Why?
|
| Xerostomia | 1 | 2018 | 10 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 235 | 0.150 |
Why?
|
| Submandibular Gland | 1 | 2018 | 18 | 0.150 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 54 | 0.140 |
Why?
|
| Osteonecrosis | 1 | 2018 | 20 | 0.140 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 636 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 40 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2018 | 127 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2022 | 9099 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 280 | 0.130 |
Why?
|
| Necrosis | 1 | 2017 | 204 | 0.120 |
Why?
|
| Brachytherapy | 1 | 2017 | 126 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 876 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 282 | 0.110 |
Why?
|
| Esophagitis | 1 | 2015 | 40 | 0.110 |
Why?
|
| Esophageal Stenosis | 1 | 2015 | 25 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 361 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 546 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2013 | 88 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2024 | 3054 | 0.090 |
Why?
|
| Quality of Life | 1 | 2020 | 1780 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2303 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 621 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1775 | 0.070 |
Why?
|
| Brain | 1 | 2017 | 2391 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2022 | 1061 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 472 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 204 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2025 | 102 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2024 | 45 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 6930 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 231 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 123 | 0.040 |
Why?
|
| Interferons | 1 | 2022 | 112 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 304 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 259 | 0.040 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 146 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2022 | 524 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 568 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 756 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 292 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 107 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 554 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1053 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 188 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 917 | 0.030 |
Why?
|
| Adolescent | 2 | 2022 | 9606 | 0.030 |
Why?
|
| Mammaplasty | 1 | 2019 | 122 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 43 | 0.030 |
Why?
|
| Infant | 1 | 2024 | 3220 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 305 | 0.030 |
Why?
|
| Mastectomy | 1 | 2019 | 262 | 0.030 |
Why?
|
| United States | 2 | 2022 | 7622 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 841 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 702 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 315 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 314 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1264 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 960 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1524 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 990 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 889 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1531 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 456 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 690 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 579 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1701 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5410 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 5899 | 0.020 |
Why?
|